Alcon agrees $475 million deal to buy U.S. eye surgery company Ivantis

Reuters2021-11-08

ZURICH, Nov 8 (Reuters) - Alcon has agreed to buy Ivantis, the maker of a tiny stent to treat glaucoma, for an initial $475 million, the Swiss eye care company said on Monday. Privately held Ivantis ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

Champion365
2021-11-08
Champion365
👍👍👍

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1165168470?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-11-08 14:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165168470","market":"us","top_or_hot":-1,"title":"Alcon agrees $475 million deal to buy U.S. eye surgery company Ivantis","media":"Reuters","content":"<div>\n<p>ZURICH, Nov 8 (Reuters) - Alcon has agreed to buy Ivantis, the maker of a tiny stent to treat glaucoma, for an initial $475 million, the Swiss eye care company said on Monday.\nPrivately held Ivantis ...</p>\n\n<a href=\"https://finance.yahoo.com/news/1-alcon-agrees-475-million-062954688.html\">网页链接</a>\n\n</div>\n","source":"lsy1612507957220","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alcon agrees $475 million deal to buy U.S. eye surgery company Ivantis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlcon agrees $475 million deal to buy U.S. eye surgery company Ivantis\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-08 14:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/1-alcon-agrees-475-million-062954688.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ZURICH, Nov 8 (Reuters) - Alcon has agreed to buy Ivantis, the maker of a tiny stent to treat glaucoma, for an initial $475 million, the Swiss eye care company said on Monday.\nPrivately held Ivantis ...</p>\n\n<a href=\"https://finance.yahoo.com/news/1-alcon-agrees-475-million-062954688.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALC","symbol_name":"Alcon Inc","start_time":0,"source_url":"https://finance.yahoo.com/news/1-alcon-agrees-475-million-062954688.html","article_id":"1165168470","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165168470","pubTimestamp":1636354224,"columns":[],"sourceInfo":{"source_id":"lsy1612507957220","name":"finance.yahoo"},"weMediaInfo":null,"summary":"ZURICH, Nov 8 (Reuters) - Alcon has agreed to buy Ivantis, the maker of a tiny stent to treat glauco","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALC":"Alcon Inc"},"translate_title":"爱尔康同意以4.75亿美元收购美国眼科手术公司Ivantis","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALC":0.9},"content_text":"ZURICH, Nov 8 (Reuters) - Alcon has agreed to buy Ivantis, the maker of a tiny stent to treat glaucoma, for an initial $475 million, the Swiss eye care company said on Monday.\nPrivately held Ivantis Hydrus Microstent makes a minimally-invasive glaucoma surgery (MIGS) device designed to lower intraocular pressure for open-angle glaucoma patients in connection with cataract surgery.\nThe microstent, roughly the size of an eyelash, reduces eye pressure by re-establishing flow through Schlemm's canal, the eye's natural outflow pathway, Alcon said.\nGlaucoma is the second-largest cause of blindness after cataracts, affecting more than 75 million people globally, it added.\nThe Swiss company, which spun off from Novartis in 2019, said the deal for California-based Ivantis strengthened its portfolio of treatments for cataract, refractive, retina and glaucoma patients.\nIt cited a study showed 65% of Hydrus Microstent patients remained medication-free at five years after having the stent implanted.\nAlcon said it may be required to make additional payments upon the achievement of certain regulatory and commercial milestones.\nThe transaction is anticipated to close in the first quarter of 2022 subject to customary closing conditions, including regulatory approval, it added.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":845544162,"gmtCreate":1636355721783,"gmtModify":1636355722581,"author":{"id":"3573653602271971","authorId":"3573653602271971","name":"Champion365","avatar":"https://static.tigerbbs.com/04df800589718231e24e96f7a0b551cc","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3573653602271971","authorIdStr":"3573653602271971"},"htmlText":"👍👍👍","listText":"👍👍👍","text":"👍👍👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/845544162","repostId":1165168470,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":true,"newsSizeData":{"likeSize":11,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1165168470","isCrawlerRequest":true}